A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)

Merck Sharp & Dohme (MSD)

Status and phase: Not yet enrolling; Phase 1

Conditions: Healthy

Treatments: Drug: MK-1167

Study type: Interventional

Funder types: Industry

Identifiers

NCT07334860

MK-1167-011 (Other Identifier)

1167-011

Details and patient eligibility

About

Researchers are looking for new ways to treat Alzheimer's disease (AD). AD is a brain disease that causes a gradual decline in memory, thinking, and ability to carry out daily tasks. MK-1167 is a study medicine designed to treat symptoms of AD. Before giving a study medicine to people with a health condition, researchers first do studies in healthy people to find a safe dose of the study medicine.

The goals of the trial are to learn:

• What happens to different forms of MK-1167 in a healthy person's body over time
• About the safety of MK-1167 and if people tolerate it

Enrollment: 16 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Is in good health
• Has a body mass index (BMI) ≥18 and ≤ 32 kg/m^2, inclusive

Exclusion criteria

• Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
• Is a smoker and/or has used nicotine or nicotine-containing products within the past 3 months.

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

16 participants in 2 patient groups

Arm 1: MK-1167 Form 2

Experimental group

Description:

Participants receive MK-1167 Form 2 orally.

Treatment:

Drug: MK-1167

Arm 2: MK-1167 Form 1

Experimental group

Description:

Participants receive MK-1167 Form 1 orally.

Treatment:

Drug: MK-1167